How much revenue does Sunho Biologics make?

Sunho Biologics reported 0 CNY in revenue for fiscal year 2024, down 100.0% from 208,000 CNY in fiscal year 2023.

What companies are similar to Sunho Biologics?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Lepu Biopharma Co., Ltd. (2157.HK), Jacobio-b (1167.HK), Immuneonco-b (1541.HK), 3D Medicines (1244.HK).

Sunho Biologics, Inc. (2898.HK) Stock

About Sunho Biologics, Inc.

Sunho Biologics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics that regulate immune microenvironment by modulating the innate and adaptive immune systems. It offers IAH0968, an antibody-dependent cell mediated cytotoxicity enhanced monoclonal antibody, which is in the Phase II clinical trials for biliary tract carcinoma and colorectal ...

At a glance

Sunho Biologics reported revenue of 0 CNY for fiscal year 2024, down 100.0% from fiscal year 2023, and net income of -79.97 million CNY.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.